cas 140675-42-9|| where to buy 1-(3,5-Difluoro-2-hydroxyphenyl)ethanone

Nombre del producto:1-(3,5-Difluoro-2-hydroxyphenyl)ethanone

IUPAC Name:1-(3,5-difluoro-2-hydroxyphenyl)ethan-1-one

Unidad de embalaje	Stock disponible	Precio($)
CM372874-5g	in stock	ǺƩ
CM372874-10g	in stock	ƻƻȋ
CM372874-25g	in stock	ŭǺƅ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 140675-42-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :140675-42-9; Fórmula molecular:C8H6F2O2; Punto de fusión:-; Código de sonrisas:CC(=O)C1=C(O)C(F)=CC(F)=C1; Densidad:

: Número de catálogo:CM372874; Peso molecular:172.13; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: STX-478; Scorpion presented initial, first-in-human clinical results from its Phase 1/2 study of STX-478 in advanced solid tumor patients in a Proffered Paper late-breaking session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Initial Phase 1 monotherapy data for STX-478, an oral, once-daily, mutant-selective, allosteric PI3Kα inhibitor, demonstrated potentially best-in-class PI3Kα inhibition, with anti-tumor activity observed in multiple cancer types, including HR+/HER2- breast cancer (BC), gynecological tumors, and other solid tumors. STX-478 was well-tolerated, including in pre-diabetic, diabetic and heavily pre-treated patients and showed no significant wild-type-mediated toxicities.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.